tbuckley/cabot-search huggingface dataset:
Renal Collision Tumor
Authors: Aparna Singh, Hina J. Shah, Borna E. Dabiri, Wendy Landman
Journal: Clinical Nuclear Medicine (2024)

Abstract A 68-year-old woman presented with chest pain and shortness of breath. Imaging revealed a left hilar mass biopsy-proven as small cell cancer. Concurrently, a macroscopic fat-containing renal lesion consistent with an angiomyolipoma was observed. Systemic therapy achieved stability in the lungs and bones, and palliative radiation targeted the left hilum. However, progressive lung disease and brain metastases necessitated stereotactic radiosurgery for brain lesions. Notably, the renal angiomyolipoma exhibited increased soft tissue component and new focal uptake on FDG PET/CT. Biopsy confirmed metastatic small cell lung cancer within the renal lesion. This case highlights a rare occurrence of a renal collision tumor involving small cell cancer and angiomyolipoma.
Struma Ovarii With Extensive Peritoneal Implants Metastasis Revealed by 99mTcO4 SPECT/CT
Authors: Hangyu Xie, Rui Huang, Jianyong Lei, Lin Li
Journal: Clinical Nuclear Medicine (2024)

Abstract Struma ovarii is a rare form of ovarian teratoma composed entirely or mainly of mature thyroid tissue. A 55-year-old woman with persistent hypogastric pain for 4 months was admitted to our hospital. She had undergone resection of struma ovarii 4 years ago. Contrast-enhanced CT shows multiple significantly enhanced nodules scattered in the abdominopelvic cavity. Pathological examination of the nodule in the left pararenal region demonstrated thyroid-like follicular epithelium. Herein, we present the 99m TcO 4 whole-body scintigraphy SPECT/CT findings of a case of struma ovarii with extensive peritoneal implants metastasis. Then, she was treated with total thyroidectomy and 131 I therapy.
What Is a Society? Building an Interdisciplinary Perspective and Why That's Important
Authors: Mark W. Moffett
Journal: Behavioral and Brain Sciences (2024)

I submit the need to establish a comparative study of societies, namely groups beyond a simple, immediate family that have the potential to endure for generations, whose constituent individuals recognize one another as members, and that maintain control over access to a physical space. This definition, with refinements and ramifications I explore, serves for cross-disciplinary research since it applies not just to nations but to diverse hunter-gatherer and tribal groups with a pedigree that likely traces back to the societies of our common ancestor with the chimpanzees. It also applies to groups among other species for which comparison to humans can be instructive. Notably, it describes societies in terms of shared group identification rather than social interactions. An expansive treatment of the topic is overdue given that the concept of a society (even the use of such synonyms as primate "troop") has fallen out of favor among biologists, resulting in a semantic mess; while sociologists rarely consider societies beyond nations, and social psychologists predominantly focus on ethnicities and other component groups of societies. I examine the relevance of societies across realms of inquiry, discussing the ways member recognition is achieved; how societies compare to other organizational tiers; and their permeability, territoriality, relation to social networks and kinship, and impermanence.We have diverged from our ancestors in generating numerous affiliations within and between societies while straining the expectation of society memberships by assimilating diverse populations. Nevertheless, if, as I propose, societies were the first, and thereafter the primary, groups of prehistory, how we came to register society boundaries may be foundational to all human "groupiness." A discipline-spanning approach to societies should further our understanding of what keeps societies together and what tear them apart.
Correction: Clinical practice and effect of carbon dioxide on outcomes in mechanically ventilated acute brain-injured patients: a secondary analysis of the ENIO study
Authors: Chiara Robba, Denise Battaglini, Abbas Abbas, Ezequiel Sarrió, Raphael Cinotti, Karim Asehnoune, Fabio S. Taccone, Patricia R. Rocco, Marcus J. Schultz, Giuseppe Citerio, Robert David Stevens, Rafael Badenes, Paër-Sélim Abback, Anaïs Codorniu, Giuseppe Citerio, Vittoria Ludovica Sala, Marinella Astuto, Eleonora Tringali, Daniela Alampi, Monica Rocco, Jessica Giuseppina Maugeri, Agrippino Bellissima, Matteo Filippini, Nicoletta Lazzeri, Andrea Cortegiani, Mariachiara Ippolito, Chiara Robba, Denise Battaglini, Patrick Biston, Mohamed Fathi Al-Gharyani, Russell Chabanne, Léo Astier, Benjamin Soyer, Samuel Gaugain, Alice Zimmerli, Urs Pietsch, Miodrag Filipovic, Giovanna Brandi, Giulio Bicciato, Ainhoa Serrano, Berta Monleon, Peter van Vliet, Benjamin Marcel Gerretsen, Iris Xochitl Ortiz-Macias, Jun Oto, Noriya Enomoto, Tomomichi Matsuda, Nobutaka Masui, Pierre Garçon, Jonathan Zarka, Wytze J. Vermeijden, Alexander Daniel Cornet, Sergio Reyes Infra Gard, Rafael Cirino Lara Domínguez, Maria Mercedes Bellini, Maria Milagros Gomez Haedo, Laura Lamot, Jose Orquera, Matthieu Biais, Delphine Georges, Arvind Baronial, Roberto Carlos Miranda-Ackerman, Francisco José Barbosa-Camacho, John Porter, Miguel Lopez-Morales, Thomas Geeraerts, Baptiste Companion, David Pérez-Torres, Estefanía Prol-Silva, Hana Basheer Yahya, Ala Khaled, Mohamed Ghulam, Cracchiolo Neville Andrea, Palma Maria Daniela, Cristian Deana, Luigi Vetrugno, Manuel J. Rivera Chavez, Rocio Mendoza Trujillo, Vincent Legros, Benjamin Brochet, Olivier Huet, Marie Geslain, Mathieu van der Jagt, Job van Steenkiste, Hazem Ahmed, Alexander Edward Coombs, Jessie Welbourne, Ana Alicia Velarde Pineda, Víctor Hugo Nubert Castillo, Mohammed A. Azab, Ahmed Y. Azzam, David Michael Paul van Meenen, Gilberto Adrian Gasca, Alfredo Arellano, Forttino Galicia-Espinosa, José Carlos García-Ramos, Ghanshyam Yadav, Amarendra Kumar Jha, Vincent Robert-Edan, Pierre-Andre Rodie-Talbere, Gaurav Jain, Sagarika Panda, Sonika Agarwal, Yashbir Deewan, Gilberto Adrian Gasca, Alfredo Arellano, Syed Tariq Reza, Md. Mozaffer Hossain, Christos Papadas, Vasiliki Chantziara, Chrysanthi Sklavou, Yannick Hourmant, Nicolas Grillot, Job van Steenkiste, Mathieu van der Jagt, Romain Pirracchio, Abdelraouf Akkari, Mohamed Abdelaty, Ahmed Hashim, Yoann Launey, Elodie Masseret, Sigismond Lasocki, Soizic Gergaud, Nicolas Mouclier, Sulekha Saxena, Avinash Agrawal, Shakti Bedanta Mishra, Samir Samal, Julio Cesar Mijangos, Mattias Haënggi, Mohan Gurjar, Marcus J. Schultz, Callum Kaye, Daniela Agustin Godoy, Pablo Alvarez, Aikaterini Ioakeimidou, Yoshitoyo Ueno, Rafael Badenes, Abdurrahmaan Ali Suei Elbuzidi, Michaël Piagnerelli, Muhammed Elhadi, Syed Tariq Reza, Mohammed Atef Azab, Jean Catherine Digitale, Nicholas Fong, Ricardo Campos Cerda, Norma de la Torre Peredo, Victoria McCredie, Elbuzidi Abdurrahmaan Ali Suei, Matthias Haenggi, Jaber Samir
Journal: Intensive Care Medicine (2024)
Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma
Authors: Romain Stammler, Van Anh Ta, Elisabeth Cohen, Caroline Ram-Wolff, Alizée Bozonnat, Gilles Battesti, Baptiste Louveau, Samia Mourah, Maxime Battistella, Hélène Moins-Teisserenc, Adèle de Masson
Journal: British Journal of Dermatology (2024)

We report three patients with Sézary syndrome who had previously been successfully treated with mogamulizumab and then failed a second course of the same treatment, despite positive CCR4 expression at the second initiation of mogamulizumab. This suggests that secondary resistance of blood disease to mogamulizumab may be independent of target expression.
Medical therapy of cardiogenic shock: Contemporary use of inotropes and vasopressors
Authors: Mauro Riccardi, Matteo Pagnesi, Ovidiu Chioncel, Alexandre Mebazaa, Gad Cotter, Finn Gustafsson, Daniela Tomasoni, Nicola Latronico, Marianna Adamo, Marco Metra
Journal: European Journal of Heart Failure (2024)
<i>B. longum</i> CKD1 enhances the efficacy of anti-diabetic medicines through upregulation of IL- 22 response in type 2 diabetic mice
Authors: Won Jun Kim, Bum Ju Kil, Chaewon Lee, Tae Young Kim, Goeun Han, Yukyung Choi, Kyunghwan Kim, Chang Hun Shin, Seung-Young Park, Heebal Kim, Myunghoo Kim, Chul Sung Huh
Journal: Gut Microbes (2024)

The gut microbiota plays a pivotal role in metabolic disorders, notably type 2 diabetes mellitus (T2DM). In this study, we investigated the synergistic potential of combining the effects of Bifidobacterium longum NBM7–1 (CKD1) with anti-diabetic medicines, LobeglitazoneⓇ (LO), SitagliptinⓇ (SI), and MetforminⓇ (Met), to alleviate hyperglycemia in a diabetic mouse model. CKD1 effectively mitigated insulin resistance, hepatic steatosis, and enhanced pancreatic β-cell function, as well as fortifying gut-tight junction integrity. In the same way, SI-CKD1 and Met- CKD1 synergistically improved insulin sensitivity and prevented hepatic steatosis, as evidenced by the modulation of key genes associated with insulin signaling, β-oxidation, gluconeogenesis, adipogenesis, and inflammation by qRT-PCR. The comprehensive impact on modulating gut microbiota composition was observed, particularly when combined with MetforminⓇ. This combination induced an increase in the abundance of Rikenellaceae and Alistipes related negatively to the T2DM incidence while reducing the causative species of Cryptosporangium, Staphylococcaceae, and Muribaculaceae. These alterations intervene in gut microbiota metabolites to modulate the level of butyrate, indole-3-acetic acid, propionate, and inflammatory cytokines and to activate the IL-22 pathway. However, it is meaningful that the combination of B. longum NBM7–1(CKD1) reduced the medicines' dose to the level of the maximal inhibitory concentrations (IC50). This study advances our understanding of the intricate relationship between gut microbiota and metabolic disorders. We expect this study to contribute to developing a prospective therapeutic strategy modulating the gut microbiota.
Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study
Authors: Tobias Else, Eric Jonasch, Othon Iliopoulos, Kathryn E. Beckermann, Vivek Narayan, Benjamin L. Maughan, Stephane Oudard, Jodi K. Maranchie, Ane B. Iversen, Cynthia M. Goldberg, Wei Fu, Rodolfo F. Perini, Yanfang Liu, W. Marston Linehan, Ramaprasad Srinivasan
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Primary analysis of the ongoing, single-arm, phase 2 LITESPARK-004 study (NCT03401788) showed clinically meaningful antitumor activity in von Hippel–Lindau (VHL) disease–associated renal cell carcinoma (RCC) and other neoplasms with belzutifan treatment. We describe results of belzutifan treatment for VHL disease–associated pancreatic lesions [pancreatic neuroendocrine tumors (pNET) and serous cystadenomas]. Patients and Methods: Adults with VHL diagnosis based on germline VHL alteration, ≥1 measurable RCC tumor, no renal tumor &amp;gt;3 cm or other VHL neoplasm requiring immediate surgery, Eastern Cooperative Oncology Group performance status of 0 or 1, and no prior systemic anticancer treatment received belzutifan 120 mg once daily. End points included objective response rate (ORR), duration of response (DOR), progression-free survival (PFS), and linear growth rate (LGR) in all pancreatic lesions and pNETs per RECIST version 1.1 by independent review committee, and safety. Results: All 61 enrolled patients (100%) had ≥1 pancreatic lesion and 22 (36%) had ≥1 pNET measurable at baseline. Median follow-up was 37.8 months (range, 36.1–46.1). ORR was 84% [51/61; 17 complete responses (CR)] in pancreatic lesions and 91% (20/22; 7 CRs) in pNETs. Median DOR and median PFS were not reached in pancreatic lesions or pNETs. After starting treatment, median LGR for pNETs was –4.2 mm per year (range, –7.9 to –0.8). Eleven patients (18%) had ≥1 grade 3 treatment-related adverse event (AE). No grade 4 or 5 treatment-related AEs occurred. Conclusions: Belzutifan continued to show robust activity and manageable safety in VHL disease–associated pNETs.
Cytonuclear Interactions and Subgenome Dominance Shape the Evolution of Organelle-Targeted Genes in the <i>Brassica</i> Triangle of U
Authors: Shenglong Kan, Xuezhu Liao, Lan Lan, Jiali Kong, Jie Wang, Liyun Nie, Jun Zou, Hong An, Zhiqiang Wu
Journal: Molecular Biology and Evolution (2024)

Abstract The interaction and coevolution between nuclear and cytoplasmic genomes are one of the fundamental hallmarks of eukaryotic genome evolution and, 2 billion yr later, are still major contributors to the formation of new species. Although many studies have investigated the role of cytonuclear interactions following allopolyploidization, the relative magnitude of the effect of subgenome dominance versus cytonuclear interaction on genome evolution remains unclear. The Brassica triangle of U features 3 diploid species that together have formed 3 separate allotetraploid species on similar evolutionary timescales, providing an ideal system for understanding the contribution of the cytoplasmic donor to hybrid polyploid. Here, we investigated the evolutionary pattern of organelle-targeted genes in Brassica carinata (BBCC) and 2 varieties of Brassica juncea (AABB) at the whole-genome level, with particular focus on cytonuclear enzyme complexes. We found partial evidence that plastid-targeted genes experience selection to match plastid genomes, but no obvious corresponding signal in mitochondria-targeted genes from these 2 separately formed allopolyploids. Interestingly, selection acting on plastid genomes always reduced the retention rate of plastid-targeted genes encoded by the B subgenome, regardless of whether the Brassica nigra (BB) subgenome was contributed by the paternal or maternal progenitor. More broadly, this study illustrates the distinct selective pressures experienced by plastid- and mitochondria-targeted genes, despite a shared pattern of inheritance and natural history. Our study also highlights an important role for subgenome dominance in allopolyploid genome evolution, even in genes whose function depends on separately inherited molecules.
Food Security to Medication Adherence—Connecting Needs
Authors: Oluwabunmi Ogungbe, Aisha Ellis, Chinedum O. Ojinnaka
Journal: JAMA Network Open (2024)

Md. Mohaimenul Islam, PhD; Ximena Oyarzun-Gonzalez, PhD; Seuli Bose-Brill, MD; Macarius M. Donneyong, PhD, MPH
Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry
Authors: Ekaterina Chelysheva, Jane Apperley, Anna Turkina, Mohamed A. Yassin, Delphine Rea, Franck E. Nicolini, Daniela Barraco, Khamida Kazakbaeva, Sukhrob Saliev, Adi Shacham Abulafia, Salam Al-Kindi, Jennifer Byrne, Harry F. Robertson, Marco Cerrano, Roman Shmakov, Evgenia Polushkina, Paolo de Fabritiis, Malgorzata Monika Trawinska, Elisabetta Abruzzese
Journal: Leukemia (2024)

The management of chronic myeloid leukemia (CML) diagnosed during pregnancy is a rare and challenging situation. We report the treatment and outcome of 87 cases diagnosed in chronic phase from 2001-2022 derived from the largest international observational registry, supported by the European LeukemiaNet (ELN), of 400 pregnancies in 299 CML women. Normal childbirth occurred in 76% without an increased rate of birth abnormalities or life-threatening events, including in patients untreated or treated with interferon-α and/or imatinib in 2nd-3rd trimester. The low birth weight rate of 12% was comparable to that seen in the normal population. Elective and spontaneous abortions occurred in 21% and 3%, respectively. The complete hematologic response rate before labor was 95% with imatinib and 47% with interferon only. No disease progression during pregnancy was observed, 28% of the patients switched their therapy at varying times after delivery. Treatment options balance the efficacy and safety for mother and infant: interferon-α can commence in the 1st trimester and continued throughout in cases of good disease control and tolerability. Because of limited placental crossing, selected tyrosine kinase inhibitors (imatinib and nilotinib) seem to be safe and effective options in 2nd and 3rd trimester while hydroxycarbamide offers few benefits.
Environmental Justice: A Missing Core Tenet of Global Health
Authors: Redeat Workneh, Merhawit Abadi, Krystle Perez, Sharla Rent, Elliott Mark Weiss, Stephanie Kukora, Olivia Brandon, Gal Barbut, Sahar Rahiem, Shaphil Wallie, Joseph Mhango, Benjamin C Shayo, Friday Saidi, Gesit Metaferia, Mahlet Abayneh, Gregory C. Valentine
Journal: The American Journal of Bioethics (2024)
Genetic adaptations for the oceanic success of fish eggs
Authors: Roderick Nigel Finn, Joan Cerdà
Journal: Trends in Genetics (2024)

Genetic adaptations of organisms living in extreme environments are fundamental to our understanding of where life can evolve. Water is the single limiting parameter in this regard, yet when released in the oceans, the single-celled eggs of marine bony fishes (teleosts) have no means of acquiring it. They are strongly hyposmotic to seawater and lack osmoregulatory systems. Paradoxically, modern teleosts successfully release vast quantities of eggs in the extreme saline environment and recorded the most explosive radiation in vertebrate history. Here, we highlight key genetic adaptations that evolved to solve this paradox by filling the pre-ovulated eggs with water. The degree of water acquisition is uniquely prevalent to marine teleosts, permitting the survival and oceanic dispersal of their eggs.
Understanding age-related pathologic changes in TDP-43 functions and the consequence on RNA splicing and signalling in health and disease
Authors: Flora Cheng, Tyler Chapman, Selina Zhang, Marco Morsch, Roger Chung, Albert Lee, Stephanie L. Rayner
Journal: Ageing Research Reviews (2024)

TAR DNA binding protein-43 (TDP-43) is a key component in RNA splicing which plays a crucial role in the aging process. In neurodegenerative diseases such as amyotrophic lateral sclerosis, frontotemporal dementia and limbic-predominant age-related TDP-43 encephalopathy, TDP-43 can be mutated, mislocalised out of the nucleus of neurons and glial cells and form cytoplasmic inclusions. These TDP-43 alterations can lead to its RNA splicing dysregulation and contribute to mis-splicing of various types of RNA, such as mRNA, microRNA, and circular RNA. These changes can result in the generation of an altered transcriptome and proteome within cells, ultimately changing the diversity and quantity of gene products. In this review, we summarise the findings of novel atypical RNAs resulting from TDP-43 dysfunction and their potential as biomarkers or targets for therapeutic development.
Targeting PKM2 signaling cascade with salvianic acid A normalizes tumor blood vessels to facilitate chemotherapeutic drug delivery
Authors: Cheng Qian, Yueke Zhou, Teng Zhang, Guanglu Dong, Mengyao Song, Yu Tang, Zhonghong Wei, Suyun Yu, Qiuhong Shen, Wenxing Chen, Jaesung P. Choi, Juming Yan, Chongjin Zhong, Li Wan, Jia Li, Aiyun Wang, Yin Lu, Yang Zhao
Journal: Acta Pharmaceutica Sinica B (2024)

Aberrant tumor blood vessels are prone to propel the malignant progression of tumors, and targeting abnormal metabolism of tumor endothelial cells emerges as a promising option to achieve vascular normalization and antagonize tumor progression. Herein, we demonstrated that salvianic acid A (SAA) played a pivotal role in contributing to vascular normalization in the tumor-bearing mice, thereby improving delivery and effectiveness of the chemotherapeutic agent. SAA was capable of inhibiting glycolysis and strengthening endothelial junctions in the human umbilical vein endothelial cells (HUVECs) exposed to hypoxia. Mechanistically, SAA was inclined to directly bind to the glycolytic enzyme PKM2, leading to a dramatic decrease in endothelial glycolysis. More importantly, SAA improved the endothelial integrity via activating the β-Catenin/Claudin-5 signaling axis in a PKM2-dependent manner. Our findings suggest that SAA may serve as a potent agent for inducing tumor vascular normalization.
Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC)
Authors: Eva Polverino, Katerina Dimakou, Letizia Traversi, Apostolos Bossios, Charles S. Haworth, Michael R. Loebinger, Anthony De Soyza, Montserrat Vendrell, Pierre-Régis Burgel, Pontus Mertsch, Melissa McDonnell, Sabina Škrgat, Luis Maiz Carro, Oriol Sibila, Menno van der Eerden, Paula Kauppi, Adam T. Hill, Robert Wilson, Branislava Milenkovic, Rosario Menendez, Marlene Murris, Tonia Digalaki, Megan L. Crichton, Sermin Borecki, Dusanka Obradovic, Adam Nowinski, Adelina Amorim, Antoni Torres, Natalie Lorent, Tobias Welte, Francesco Blasi, Eva Van Braeckel, Josje Altenburg, Amelia Shoemark, Michal Shteinberg, Wim Boersma, J. Stuart Elborn, Stefano Aliberti, Felix C. Ringshausen, James D. Chalmers, Pieter C. Goeminne
Journal: Journal of Allergy and Clinical Immunology (2024)

Asthma is commonly reported in patients with a diagnosis of bronchiectasis.
The emergence of multiscale connectomics-based approaches in stroke recovery
Authors: Shahrzad Latifi, S. Thomas Carmichael
Journal: Trends in Neurosciences (2024)

Stroke is a leading cause of adult disability. Understanding stroke damage and recovery requires deciphering changes in complex brain networks across different spatiotemporal scales. While recent developments in brain readout technologies and progress in complex network modeling have revolutionized current understanding of the effects of stroke on brain networks at a macroscale, reorganization of smaller scale brain networks remains incompletely understood. In this review, we use a conceptual framework of graph theory to define brain networks from nano- to macroscales. Highlighting stroke-related brain connectivity studies at multiple scales, we argue that multiscale connectomics-based approaches may provide new routes to better evaluate brain structural and functional remapping after stroke and during recovery.
Gut-associated lymphoid tissue: a microbiota-driven hub of B cell immunity
Authors: Mats Bemark, Michael J. Pitcher, Chiara Dionisi, Jo Spencer
Journal: Trends in Immunology (2024)

The diverse gut microbiota, which is associated with mucosal health and general wellbeing, maintains gut-associated lymphoid tissues (GALT) in a chronically activated state, including sustainment of germinal centers in a context of high antigenic load. This influences the rules for B cell engagement with antigen and the potential consequences. Recent data have highlighted differences between GALT and other lymphoid tissues. For example, GALT propagates IgA responses against glycans that show signs of having been generated in germinal centers. Other findings suggest that humans are among those species where GALT supports the diversification, propagation, and possibly selection of systemic B cells. Here, we review novel findings that identify GALT as distinctive, and able to support these processes.